Streetwise Reports' Article Archives — Current Month (4)
AI Breakthroughs Drive New Momentum in Oncology Research (12/03/2025)
Rakovina Therapeutics Inc. (RKV:TSX.V) reported financial and operational results for Q3, detailing continued progress across its AI-enabled DNA Damage Response programs. The company highlighted new scientific data, expanded collaborations, and increased visibility at major oncology conferences.
Analyst: Scientific Instrument Co.'s Q3/25 Results 'Soft' (12/02/2025)
Nanalysis Scientific Corp. (NSCI:TSX.V; NSCIF:OTC; 1N1:FSE) has its price target lowered as a result, but is expected to improve its financials in the near term, noted a Leede Financial Inc. report.
Biotech Co. Advances Precision Psychiatry Breakthrough Pipeline While Analysts' Sentiment Remains Positive (12/01/2025)
Alto Neuroscience Inc. (ANRO:NYSE) continues moving its clinical programs forward, receives regulatory clarity and raises US$50 million, during the past four months. Read on for analysts' thoughts on this biopharma.
Biotech Co.'s Q3/25 Progress on Lead Programs Steady (12/01/2025)
Alto Neuroscience Inc.'s (ANRO:NYSE) clinical execution and regulatory momentum advance the firm's biomarker-guided precision psychiatry pipeline, noted an H.C. Wainwright & Co. report.
More Archives
2025Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
